mometasone topical (Rx)

Brand and Other Names:Elocon
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

cream/lotion/ointment

  • 0.1%

Inflammatory Hyperkeratotic Dermatosis

Apply cream, lotion or ointment to affected area qDay

Administration

Do not use with occlusive dressings

Other Indications & Uses

Dermatosis-associated inflammation and pruritus

Potency: Medium

Dosage Forms & Strengths

cream/lotion/ointment

  • 0.1%

Inflammatory Hyperkeratotic Dermatosis

<2 years: Safety and efficacy not established

2 years or older: As adults: apply cream, lotion or ointment to affected area qDay

Use beyond 3 weeks not studied

Next:

Interactions

Interaction Checker

and mometasone topical

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (1)

            • mifepristone

              mifepristone, mometasone topical. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Mifepristone is contraindicated in patients on long-term corticosteriod treatment due to increase risk of adrenal insufficiency.

            Serious - Use Alternative (1)

            • aldesleukin

              mometasone topical decreases effects of aldesleukin by unspecified interaction mechanism. Avoid or Use Alternate Drug.

            Monitor Closely (5)

            • ceritinib

              mometasone topical decreases effects of ceritinib by Other (see comment). Modify Therapy/Monitor Closely. Comment: Closely monitor for severe hyperglycemia (serum glucose >250 mg/dL) and treat appropriately. Patients with history of diabetes or glucose intolerance are at increased risk. .

            • corticorelin

              mometasone topical decreases effects of corticorelin by pharmacodynamic antagonism. Use Caution/Monitor. Recent or current corticosteroid therapy may blunt the response to corticorelin, potentially interfering with the corticorelin stimulation test results.

            • deferasirox

              mometasone topical decreases effects of deferasirox by unspecified interaction mechanism. Use Caution/Monitor. Due to the risk for GI bleeding and irritation/ulceration associated with deferasirox, exercise caution when using with corticosteroids, that can also cause gastrointestinal ulceration and/or bleeding.

            • hyaluronidase

              mometasone topical decreases effects of hyaluronidase by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Patients receiving larger doses of corticosteriods may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.

            • omacetaxine

              omacetaxine, mometasone topical. Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. Comment: Concomitant use with omacetaxine and mometasone topical may enhance the risk of infections and myelosuppression.

            Minor (0)

              Previous
              Next:

              Adverse Effects

              Frequency Not Defined

              Burning

              Itching

              Pruritus

              Rosacea

              Postmarketing Reports

              Irritation

              Dryness

              Folliculitis

              Hypertrichosis

              Acneiform eruptions

              Hypopigmentation

              Perioral dermatitis

              Allergic contact dermatitis

              Secondary infection

              Skin atrophy

              Striae

              Miliaria

              Blurred vision

              Cataracts

              Glaucoma

              Increased intraocular pressure

              Central serous chorioretinopathy

              Previous
              Next:

              Warnings

              Contraindications

              Hypersensitivity

              Cautions

              Safety/efficacy in children use for longer than 3 wk not established; pediatric patients may be more susceptible to systemic toxicity

              Do not use with occlusive dressings

              Not for acne, rosacea, perioral dermatitis, diaper dermatitis

              If concomitant skin infections are present or develop, use appropriate antifungal or antibacterial agent; if favorable response does not occur promptly, therapy should be discontinued until infection has been adequately controlled

              If irritation develops, discontinue therapy and institute appropriate therapy; allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation; corroborate observation with appropriate diagnostic patch testing

              Use of topical corticosteroids may increase risk of posterior subcapsular cataracts and glaucoma; cataracts and glaucoma reported in postmarketing experience with therapy; avoid contact with eyes; advise patients to report any visual symptoms and consider referral to ophthalmologist for evaluation

              Endocrine system effects

              • Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with potential for glucocorticosteroid insufficiency; this may occur during treatment or after withdrawal of treatment
              • Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can be produced in some patients by systemic absorption of topical corticosteroids while on treatment
              • Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include use of high potency steroids, large treatment surface areas, prolonged use, use of occlusive dressing, altered skin barrier, liver failure and young age
              • Because of potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression; this may be done by using the adrenocorticotropic hormone (ACTH) stimulation test
              • If HPA axis suppression documented, attempt to gradually withdraw drug, to reduce frequency of application, or to substitute a less potent corticosteroid; recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids; infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur, requiring supplemental systemic corticosteroids
              • Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios
              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy Category: C

              Lactation: use caution

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Absorption: 0.4%

              Metabolism: hepatic P450 enzyme CYP3A4

              Excretion: N/A

              Potency

              Medium

              Relative potency: ointment >cream >lotion >solution

              Very-high: clobetasol, diflorasone diacetate ointment 0.05%, halobetasol

              High: betamethasone dipropionate 0.05%, amcinonide, fluocinonide, desoximetasone, mometasone, diflorasone emollient 0.05%, halcinonide

              Medium: triamcinolone, betamethasone valerate 0.1%, fluticasone, flurandrenolide, fluocinolone 0.025%, hydrocortisone

              Mild: hydrocortisone 0.5, 1, 2.5% base, desonide, alclometasone

              Mechanism of Action

              Anti-inflammatory corticosteroid

              Previous
              Next:

              Images

              BRAND FORM. UNIT PRICE PILL IMAGE
              mometasone nasal
              -
              50 mcg/actuation aerosol
              mometasone nasal
              -
              50 mcg/actuation aerosol
              mometasone nasal
              -
              50 mcg/actuation aerosol
              Sinuva sinus
              -
              1,350 mcg implant
              mometasone topical
              -
              0.1 % ointment
              mometasone topical
              -
              0.1 % cream
              mometasone topical
              -
              0.1 % cream
              mometasone topical
              -
              0.1 % ointment
              mometasone topical
              -
              0.1 % ointment
              mometasone topical
              -
              0.1 % cream
              mometasone topical
              -
              0.1 % cream
              mometasone topical
              -
              0.1 % ointment
              mometasone topical
              -
              0.1 % ointment
              mometasone topical
              -
              0.1 % solution
              mometasone topical
              -
              0.1 % ointment
              mometasone topical
              -
              0.1 % ointment
              mometasone topical
              -
              0.1 % cream
              mometasone topical
              -
              0.1 % cream
              mometasone topical
              -
              0.1 % ointment
              mometasone topical
              -
              0.1 % solution
              mometasone topical
              -
              0.1 % solution
              mometasone topical
              -
              0.1 % solution
              Asmanex Twisthaler inhalation
              -
              220 mcg/ actuation (14) aerosol
              Asmanex Twisthaler inhalation
              -
              220 mcg/ actuation (60) aerosol
              Asmanex Twisthaler inhalation
              -
              220 mcg/ actuation (120) aerosol
              Asmanex Twisthaler inhalation
              -
              110 mcg/ actuation (30) aerosol
              Asmanex Twisthaler inhalation
              -
              220 mcg/ actuation (30) aerosol
              Asmanex HFA inhalation
              -
              100 mcg/actuation aerosol
              Asmanex HFA inhalation
              -
              200 mcg/actuation aerosol
              Asmanex HFA inhalation
              -
              50 mcg/actuation aerosol

              Copyright © 2010 First DataBank, Inc.

              Previous
              Next:

              Patient Handout

              A Patient Handout is not currently available for this monograph.
              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.